Advancing patient care through innovations in urology.
Driving scientific innovation to improve patient care.
Offering exceptional career possibilities.
Our Mission
Advancing the care of patients living with urological conditions
Our Science
Delivering bold innovations for patients and providers
Working With Us
Come see what Urovant Sciences has to offer
Urovant Sciences is a biopharmaceutical company focused on developing and commercializing innovative therapies for urological conditions.
Our goal is to be a leading specialty company, recognized and trusted by patients and providers for our commitment to urology.
Urovant Sciences is driving scientific innovation to improve the quality of life for patients with urological conditions that are overlooked, misunderstood or not well managed.
Careers at Urovant Sciences offer exceptional possibilities.
When you join Urovant Sciences, you become part of our world-class team and dynamic culture where you have the opportunity to develop and grow, personally and professionally.
December 23, 2020
Urovant Sciences Announces U.S. FDA Approval of GEMTESA® (vibegron) 75 mg Tablets for the Treatment of Patients with Overactive Bladder (OAB)
November 24, 2020
Urovant Sciences Announces Topline Data from Phase 2a Study of Vibegron for the Treatment of Irritable Bowel Syndrome (IBS) Pain Did Not Meet Primary Endpoint
November 19, 2020
Urovant Sciences Announces Positive Clinical Efficacy and Safety Data from Vibegron EMPOWUR Long Term Extension Study